Nantkwest (NASDAQ:NK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday. The firm presently has a $5.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 8.70% from the company’s current price.

According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “

Several other brokerages have also commented on NK. BidaskClub lowered Nantkwest from a “sell” rating to a “strong sell” rating in a research note on Friday, September 22nd. Raymond James Financial reaffirmed a “hold” rating on shares of Nantkwest in a research note on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $5.25.

Shares of Nantkwest (NASDAQ NK) opened at $4.60 on Friday. The stock has a market capitalization of $363.11, a P/E ratio of -3.62 and a beta of 3.41. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. Nantkwest has a 1 year low of $2.71 and a 1 year high of $8.45.

Institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC acquired a new position in Nantkwest in the second quarter worth $102,000. Gotham Asset Management LLC acquired a new position in Nantkwest in the second quarter worth $104,000. State of Wisconsin Investment Board acquired a new position in Nantkwest in the second quarter worth $129,000. Nationwide Fund Advisors boosted its stake in Nantkwest by 67.6% in the second quarter. Nationwide Fund Advisors now owns 17,302 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 6,977 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in Nantkwest by 9.0% in the second quarter. New York State Common Retirement Fund now owns 19,400 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 1,599 shares in the last quarter. 19.11% of the stock is currently owned by institutional investors.

WARNING: “Nantkwest (NK) Upgraded to Buy at Zacks Investment Research” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/nantkwest-nk-upgraded-to-buy-at-zacks-investment-research.html.

Nantkwest Company Profile

Get a free copy of the Zacks research report on Nantkwest (NK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.